logo
This week in EV tech: Audi exemplifies auto industry's EV holding pattern

This week in EV tech: Audi exemplifies auto industry's EV holding pattern

Digital Trends15 hours ago

The road to the future runs through the present, and it's not a straight line. This week, we're focusing on how Audi is negotiating the twists and turns on the way to an electrified future.
EVs are here to stay at Audi, but a gasoline crossover SUV is still the automaker's bestselling model, and it's not ready to risk those sales just yet. That's why the 2025 Audi Q5 received a top-to-bottom overhaul for this model year, bringing its tech features and styling up to date without altering the what has proven to be a very popular package. By maintaining parallel lineups of electric and internal-combustion cars, Audi hopes to give customers more choices. But that doesn't completely level the playing field.
The new Q5 may have yesterday's powertrain, but Audi isn't holding back on tech. It features the same electrical architecture, operating system, and three-screen dashboard display as the latest Audi EVs, like the Q6 e-tron. So aside from a little engine noise, there's little difference in what you can see and interact with from the driver's seat.
It's not just the infotainment systems. The Q5 and Q6 e-tron are close in size, with similar space for passengers across their two rows of seats. The Q6 e-tron has a bit more cargo space, but not as much as you'd think given the lack of a bulky engine, transmission, and driveshafts. The two SUVs also have similar styling but, having now driven both, we can say that the Q5 is the more pleasant of the two.
More than a difference of powertrain tech
The interiors may look similar, but the materials used in the Q5 felt nicer to the touch. And the gasoline SUV had a much more refined chassis, with crisper handling and plusher ride quality, than its EV counterpart. The base Q5 is also quicker than a base Q6 e-tron in a straight line (quicker versions of the EV are available), although the rough shifts from our test car's dual-clutch transmission had us missing the smoother acceleration of an EV, even if it took a few more tenths of a second to reach 60 mph.
Recommended Videos
There's also more differentiation between the Q5 and its sportier SQ5 counterpart than the Q6 e-tron and the SQ6 e-tron. The latter didn't do much to justify its price premium over base models, but the SQ5 at least had a somewhat more vivacious character. The e-tron GT proves that Audi knows how to build a sporty EV, and there are plenty of other examples like the Ford Mustang Mach-E and Hyundai Ioniq 5 N. But these SUVs show that it's harder to build that level of differentiation into a mid-range electric offering like Audi's 'S' models than more extensively-engineered performance EVs.
And while some EVs have closed the price gap with combustion models, the Q6 e-tron's $65,095 base price is a big step up from the $53,795 starting price of a Q5. Audi has done a great job of maintain parity on tech and features between gasoline and electric models, but that means the Q6 e-tron will likely appeal mainly to brand loyalists who specifically want an EV. It's hard to imagine many powertrain-agonistic customers choosing it after driving a Q5 — or looking at its window sticker.
Policy uncertainty has automakers hedging their bets
Audi's approach is typical of the current moment, though. In the United States, at least, automakers are settling into holding pattern on EV adoption as they look to balance unpredictable rates of EV sales and the fallout from Trump Administration policies with the need to capitalize on investments already made in EV production.
The industry is currently holding its breath as the Trump Administration undertakes a trade war with China that could affect the supply of rare earth minerals that are a key part of the EV supply chain. Automotive News reported earlier this week that automakers were 'in full panic' over the rare earth situation. A framework was reportedly reached later in the week, but that's subject to further negotiation and potential future reversals by the mercurial U.S. president.
Trump's policies are ostensibly aimed at bringing more auto manufacturing back to the U.S., but as another big piece of news from this week shows, that doesn't necessarily benefit EVs. General Motors announced that it would task its Orion Assembly plant in Michigan to build gasoline SUVs and pickup trucks, rather than the EVs previously planned.
The move, part of a $4 billion investment that will also bring production of the gasoline Chevrolet Blazer and Equinox to the U.S. from Mexico, was criticized by the Sierra Club, which accused GM of all but abandoning a previous 'aspiration' to sell only electric light-duty vehicles by 2035. But at an investor conference Wednesday, GM CFO Paul Jacobson defended the move as a necessary response to both Trump's tariffs and strong demand for gasoline vehicles.
And on Thursday, Trump signed an order revoking a California regulatory waiver allowing the state to end sales of most new internal-combustion vehicles by 2035. This is a rerun of policy from the previous Trump Administration, which also sought to curtail California's emissions authority. California and 10 other states quickly filed suit in response, but for now the situation creates yet more uncertainty for automakers.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Baird Lowers Tesla (TSLA) to Hold, Citing Valuation and Robotaxi Risk
Baird Lowers Tesla (TSLA) to Hold, Citing Valuation and Robotaxi Risk

Yahoo

time18 minutes ago

  • Yahoo

Baird Lowers Tesla (TSLA) to Hold, Citing Valuation and Robotaxi Risk

Tesla Inc. (NASDAQ:TSLA) is one of the 10 best tech stocks to buy according to billionaires right now. On June 9, Ben Kallo of Robert W. Baird downgraded Tesla from Buy to Hold mainly on valuation concerns, while keeping his price target unchanged at $320. In his view, much of the recent upside in the stock, up over 20% since Q1 earnings, has already factored in the excitement around Tesla's planned robotaxi service and the prospect of a lower-cost electric vehicle. Hadrian / Kallo cited two key areas of concern behind the downgrade. First, he flagged elevated market expectations ahead of Tesla's upcoming robotaxi event, which he believes could be difficult to meet. Second, he raised questions around 'key-man' risk, pointing to ongoing uncertainty tied to CEO Elon Musk's central role in the company's strategic direction. While Musk has resigned from the Department of Government Efficiency (DOGE), it may still take time for him to recoup investor confidence. While Kallo still considers Tesla a core long-term holding, he expressed skepticism about the near-term ramp-up of the robotaxi program, describing current projections as potentially too ambitious. He also noted that Elon Musk's political affiliations, particularly his perceived alignment with former President Trump, could introduce additional headline and regulatory risk moving forward. Tesla Inc. (NASDAQ:TSLA) is an EV manufacturer and clean energy company known for its innovative approach to sustainable transportation and energy solutions. It designs, manufactures, and sells electric vehicles, battery energy storage systems, solar products, and related services. It currently manufactures five different consumer vehicles: the Model 3, Y, S, X, and the Cybertruck. While we acknowledge the potential of TSLA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)
QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)

Yahoo

time2 hours ago

  • Yahoo

QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)

QIAGEN to create a multimodal panel using next-generation sequencing (NGS) technology for detecting clinically relevant gene alterations in hematological malignancies Companion diagnostic to identify key disease-causing mutations in patients with MPNs, with an initial focus on mutant CALR the second most common driver of MPNs Panel to be validated on Illumina NextSeq 550Dx platform for use with whole blood samples Partnership supports Incyte's extensive portfolio in myeloproliferative neoplasms, including INCA033989, and enhances QIAGEN's onco-hematology diagnostics pipeline VENLO, Netherlands & WILMINGTON, Del., June 15, 2025--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) and Incyte (Nasdaq: INCY) today announced a new global collaboration to develop a novel diagnostic panel to support Incyte's extensive portfolio of investigational therapies for patients with myeloproliferative neoplasms (MPNs), a group of rare blood cancers, including Incyte's monoclonal antibody INCA033989, targeting mutant calreticulin (mutCALR), which is being developed in myelofibrosis (MF) and essential thrombocythemia (ET). Under the terms of the Master Collaboration Agreement with Incyte, QIAGEN will develop a multimodal panel using next-generation sequencing (NGS) technology for detecting clinically relevant gene alterations in hematological malignancies. The panel will be validated using the next-generation sequencing (NGS) technology and the Illumina NextSeq 550Dx platform as part of QIAGEN's partnership with Illumina (NASDAQ: ILMN) to leverage its NGS diagnostic platforms for patient testing by laboratories worldwide. QIAGEN will support regulatory submission processes and market access activities across the United States, European Union and Asia-Pacific regions. Myeloproliferative neoplasms are a group of diseases representing about 40% of hematological malignancies, characterized by chronic accumulation of different mature blood cell types in blood. Identifying genomic aberrations in clinically relevant biomarkers like CALR are shown to be key, especially in MPNs. Incyte is at the forefront of developing novel therapies, including INCA033989 for patients with mutCALR ET or MF, that target only malignant cells, sparing normal cells. The use of companion diagnostics helps guide clinicians in making treatment decisions that can lead to better patient outcomes. "Following our presentation of positive, late-breaking data from our first-in-class mutCALR-targeted antibody at EHA, we are excited to announce this partnership with QIAGEN, which will facilitate CALR testing for patients with MPNs on a global basis. The development of companion diagnostics for mutCALR, coupled with the potential for new medicines to selectively target disease-initiating cells, is a critical step toward changing the course of disease in patients with ET and MF," said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. "As a partner, QIAGEN has the proven expertise in companion diagnostics development and approvals needed to support our ongoing work and commitment to transforming the treatment of patients with CALR-mutant MPNs." "Together with Incyte we are building a multimodal companion diagnostic using a powerful technology like next-generation sequencing to facilitate highly accurate testing for several blood cancer genes at once," said Jonathan Arnold, Vice President and Head of Partnering for Precision Diagnostics at QIAGEN. "This new partnership strengthens our role in offering companion diagnostics for the growing number of biomarkers being discovered in onco-hematology and maximizing the clinical utility of the diagnostic for payor and patient benefit, thus supporting the work of innovative, science-driven companies like Incyte to improve patient outcomes." About Mutations in Calreticulin (mutCALR) Calreticulin (CALR) is a protein involved in the regulation of cellular calcium levels and normal protein production. Somatic, or non-inherited, DNA mutations in the CALR gene (mutCALR) can result in abnormal protein function and lead to the development of myeloproliferative neoplasms (MPNs),i a closely related group of clonal blood cancers in which the bone marrow functions abnormally, overproducing blood Among the two types of MPNs, essential thrombocythemia (ET) and myelofibrosis (MF), mutCALR drives 25-35% of all cases.i,ii About QIAGEN QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions, enabling customers to extract and gain valuable molecular insights from samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis while bioinformatics software and knowledge bases can be used to interpret data to find actionable insights. Automation solutions bring these processes together into seamless and cost-effective workflows. QIAGEN serves over 500,000 customers globally in Life Sciences (academia, pharma R&D and industrial applications, primarily forensics) and Molecular Diagnostics for clinical healthcare. As of March 31, 2025, QIAGEN employed approximately 5,700 people in over 35 locations worldwide. For more information, visit QIAGEN is a pioneer in precision medicine and the leader in collaborating with pharmaceutical and biotechnology companies to develop companion diagnostics, having more than 30 master collaboration agreements with global pharmaceutical and biotechnology companies to develop and commercialize diagnostic tests. QIAGEN's offering to these companies encompasses technologies ranging from polymerase chain reaction (PCR), near-patient testing and digital PCR (dPCR) to next-generation sequencing (NGS), and sample types from liquid biopsy to tissue. It also spans disease areas from cancer to non-oncology diseases such as neurodegenerative, inflammatory, and metabolic diseases – including 16 FDA-approved PCR-based companion diagnostics. For more information about QIAGEN's efforts in precision medicine please visit About Incyte A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia. For additional information on Incyte, please visit or follow us on social media: LinkedIn, X, Instagram, Facebook, YouTube. QIAGEN Forward-Looking Statement Certain statements in this press release may constitute forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements, including those regarding QIAGEN's products, development timelines, marketing and / or regulatory approvals, financial and operational outlook, growth strategies, collaborations and operating results - such as expected adjusted net sales and adjusted diluted earnings - are based on current expectations and assumptions. However, they involve uncertainties and risks. These risks include, but are not limited to, challenges in managing growth and international operations (including the effects of currency fluctuations, regulatory processes and logistical dependencies), variability in operating results, commercial development for our products to customers in the Life Sciences and clinical healthcare, changes in relationships with customers, suppliers or strategic partners; competition and rapid technological advancements; fluctuating demand for QIAGEN's products due to factors such as economic conditions, customer budgets and funding cycles; obtaining and maintaining regulatory approvals for our products; difficulties in successfully adapting QIAGEN's products into integrated solutions and producing these products; and protecting product differentiation from competitors. Additional uncertainties may arise from market acceptance of new products, integration of acquisitions, governmental actions, global or regional economic developments, natural disasters, political or public health crises, and other "force majeure" events. There is also no guarantee that anticipated benefits from restructuring programs and acquisitions will materialize as expected. For a comprehensive overview of risks, please refer to the "Risk Factors" contained in our most recent Annual Report on Form 20-F and other reports filed with or furnished to the U.S. Securities and Exchange Commission. Incyte Forward-Looking Statements Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding the potential for Incyte's mut-CALR targeted antibody (INCA033989) to provide a potential treatment option for patients with ET or MF, contain predictions, estimates and other forward-looking statements. These forward-looking statements are based on Incyte's current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; determinations made by the FDA, EMA, and other regulatory authorities; the efficacy or safety of Incyte and its partners' products; the acceptance of Incyte and its partners' products in the marketplace; market competition; sales, marketing, manufacturing and distribution requirements; and other risks detailed from time to time in our reports filed with the U.S. Securities and Exchange Commission, including our annual report on Form 10-K and our quarterly report on Form 10-Q for the quarter ended March 31, 2025. Incyte disclaims any intent or obligation to update these forward-looking statements. Source: QIAGEN Precision Medicine i Raghavan, M., Wijeyesakere S.J., Peters L.R., Del Cid N. (2013) Calreticulin in the immune system: ins and outs. Trends in Immunology, 34(1):13-21. Link to source ( Nangalia J. Massie C.E., Baxter E.J., Nice F.L., et al. (2013) Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. New England Journal of Medicine, 369(25):2391-2405. Link to source ( Klampfl T., Gisslinger, H., Harutyunyan A.S., et al. (2013) Somatic mutations of calreticulin in myeloproliferative neoplasms. New England Journal of Medicine, 369(25):2379-2390. Link to source ( View source version on Contacts Contacts QIAGEN:Investor Relationsir@ Public Relationspr@ Contacts Incyte:Mediamedia@ Investorsir@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store